Redox regulation of cell activation and transformation by ADF/TRX (human thioredoxin) (Meeting abstract). NLM AIDSLINE Important note: Information in this article was accurate in 1993. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Redox regulation of cell activation and transformation by ADF/TRX (human thioredoxin) (Meeting abstract).

International Symposium on Cancer, Sapporo Cancer Seminar: Oxyradicals and Anti-oxidative Responses in Cancer. July 14-16, 1992, Sapporo, Japan, p. 46, 1992.. Unique Identifier : AIDSLINE ICDB/93690047
Taniguchi Y; Kawabe T; Masutani H; Nakamura H; Matsuda M; Okamoto T; Yodoi J; Dept. of Biological Responses, Inst. for Virus Res., Kyoto Univ.,; 53 Shogoin, Kawahara-cho, Sakyo-ku, Kyoto 606, Japan


Abstract: Human T-lymphotropic virus type 1 (HTLV-1)-transformed T cells overexpress interleukin-2 receptor alpha chain (IL-2R alpha) and adult T-cell leukemia-derived factor (ADF), originally defined as an IL-2R inducer. Subsequent ADF cDNA cloning showed that ADF is a human homolog of thioredoxin (TRX), an endogenous thiol-reducing protein. Several cytokines, such as 3B6-IL-1, MP6-BSF and eosinophil cytotoxicity-enhancing factor, have been shown to be identical or related to ADF. In addition to cytokine/cocytokine activity to enhance the growth and activation of lymphoid cells, rADF has a potent reducing activity catalyzing the proton transfer between thiol residues of cysteine-containing proteins. rADF and thioredoxin also has a radical scavenging activity catalyzing hydrogen peroxide (H2O2). rADF also protects the cells from cytotoxicity by TNF alpha, as well as H2O2 (submitted). The expression of ADF/TRX is variable depending on the cell types and markedly enhanced in the cellular transformation following infection by HTLV-1, EBV and human papilloma virus. Because the induction of IL-2R alpha in HTLV-1 infection is dependent on NF-kappa B, we investigated whether rADF/TXR controls the regulatory effect of NF-kappa B on the IL-2R alpha-enhancer site containing NF-kappa B binding site. Binding of protein(s) to the kappa B motif in the IL-2R alpha enhancer was lost by oxidation in vitro and was completely restored by rADF/TRX in the presence of TRX reductase and NADPH. However, the activity of oxidized protein(s) binding to the kappa B motif was not restored by mutated ADF/TRX without reducing activity. When ADF/TRX was overexpressed in natural killer YT cells by transfecting its expression vector, the transcription from the promotor/enhancer of IL-2R alpha was augmented. These results demonstrated that the redox regulation via ADF/TRX may play an important role in the activation of NF-kappa B both in vitro and in vivo. As is the case of HIV LTR activation by NF-kappa B. ADF/TRX may be required for the activation of IL-2R alpha gene by NF-kappa B and possibly for the transforming process of HTLV-1-positive cells. (4 Refs)
Keywords: Cell Survival *Cell Transformation, Neoplastic *Cell Transformation, Viral Cloning, Molecular DNA Herpesvirus 4, Human/PATHOGENICITY Human HTLV-I/PATHOGENICITY Oxidation-Reduction Papillomavirus/PATHOGENICITY Thioredoxin/GENETICS/*METABOLISM ABSTRACTKWDcellsurvivalKWDcelltransformation,neoplasticKWDcelltransformation,viralcloning,moleculardnaherpesvirus4,human/pathogenicityhumanhtlv-i/pathogenicityoxidation-reductionpapillomavirus/pathogenicitythioredoxin/genetics/KWDmetabolismabstract
930430
M9340823

Copyright © 1993 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1993. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1993. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .